A biopharmaceutical business that specializes in the extensive research.

Alimera Sciences inks Protection and Loan Contract with Hercules Technology Development Capital Alimera Sciences, Inc. , a biopharmaceutical business that specializes in the extensive research, development and commercialization of prescription ophthalmic pharmaceuticals, today that its UK subsidiary announced, Alimera Sciences Limited , has entered right into a Security and Loan Agreement with Hercules Technology Growth Capital, Inc. for a term mortgage in the principal amount as high as $35 million. Under the agreement, Hercules is advancing $10 million to Small and will advance the rest of the $25 million in the event the U.S. The proceeds of the original funding of $10 million beneath the term mortgage will be used to pay off an existing term mortgage payable to Silicon Valley Bank also to provide extra functioning capital for general corporate reasons.I am pleased to be engaged in the ongoing Stage IIb in the adult lung transplant patient population and look forward to continuing enrollment in this trial.’ As a complete result of this study, Alnylam initiated earlier this season a multi-center, global, randomized, double blind, placebo-controlled Stage IIb trial for ALN-RSV01 in RSV-infected adult lung transplant individuals. This new study aims to repeat and extend the full total results of the Phase IIa study.